Mayne Pharma announces PBS listing of Kapanol for chronic breathlessness

Mayne Pharma

27 August 2019 - Mayne Pharma Group is pleased to announce the PBS has approved the reimbursement of Kapanol low dose sustained-release 10 mg and 20 mg morphine capsules for the treatment of chronic breathlessness in palliative care patients with advanced disease.

From 1 September 2019, the use of Kapanol for chronic breathlessness will be a new indication on the PBS Palliative Care Schedule. 

This is an addition to Kapanol’s current PBS General Schedule listing for use in chronic severe disabling pain unresponsive to non-opioid analgesics.

Read Mayne Pharma press release

Michael Wonder

Posted by:

Michael Wonder